Ye Weiguo 4

What Happened
Ye Weiguo, Chief Operating Officer of Gyre Therapeutics (GYRE), exercised 2,800 stock options on June 11, 2026 at an exercise price of $0.75 per share (cost $2,100), and sold 2,800 shares in an open-market transaction the same day at a weighted-average price of $6.17, generating gross proceeds of approximately $17,276. The filing also shows a derivative disposition of 2,800 shares at $0.00 related to the exercise/settlement.

Key Details

• Transaction date: 2026-06-11. Filing date: 2026-06-15. (No late-filing flag noted in the provided excerpt.)
• Exercise: 2,800 options @ $0.75 = $2,100 paid.
• Sale: 2,800 shares @ weighted avg $6.17 = ~$17,276 gross proceeds. Reported sale prices ranged $6.16–$6.18 (footnote F1).
• Derivative line: 2,800 shares reported disposed at $0.00 (likely reflects conversion/settlement of the exercised options); options are fully vested (footnote F2).
• Shares owned after the transactions: not disclosed in the provided filing excerpt.

Context
Because the options were exercised and the resulting shares were sold the same day, this effectively looks like a cashless exercise where the insider converted vested options into cash. Footnote F1 explains the sale price is a weighted average across multiple trades; the company or SEC staff can request a breakdown of trades by price. As always, these transactions are factual records of insider activity and do not, by themselves, indicate the insider’s future view of the company.